gemfibrozil ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1285 25812-30-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • gemfibrosil
  • gemfibrozil
  • decrelip
  • lopizid
A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol.
  • Molecular weight: 250.34
  • Formula: C15H22O3
  • CLOGP: 3.94
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 46.53
  • ALOGS: -3.95
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.20 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.02 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 79.89 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 98 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Dec. 21, 1981 FDA PFIZER PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rhabdomyolysis 224.26 13.05 123 10030 38904 50556067
Drug hypersensitivity 72.44 13.05 157 9996 250853 50344118
Blood triglycerides increased 57.66 13.05 33 10120 11279 50583692
Coronary artery disease 54.02 13.05 46 10107 29680 50565291
Myocardial infarction 46.38 13.05 72 10081 88955 50506016
Blood creatine phosphokinase increased 46.27 13.05 40 10113 26327 50568644
Acute interstitial pneumonitis 42.91 13.05 12 10141 611 50594360
Cardiac failure congestive 35.51 13.05 62 10091 84320 50510651
Myopathy 34.52 13.05 22 10131 9117 50585854
Cerebrovascular accident 32.83 13.05 64 10089 94616 50500355
Myalgia 31.54 13.05 74 10079 124245 50470726
Pancreatitis 30.32 13.05 40 10113 42574 50552397
Pancreatitis acute 28.11 13.05 29 10124 23783 50571188
Drug interaction 27.26 13.05 95 10058 199526 50395445
Lip infection 23.66 13.05 5 10148 76 50594895
Blood glucose increased 23.26 13.05 47 10106 71277 50523694
Diabetes mellitus 21.89 13.05 37 10116 48996 50545975
Off label use 21.54 13.05 39 10114 474387 50120584
Drug intolerance 20.75 13.05 9 10144 219095 50375876
Drug ineffective 20.45 13.05 90 10063 819243 49775728
Tendon rupture 19.35 13.05 14 10139 7130 50587841
Bursitis 17.66 13.05 22 10131 22113 50572858
Microalbuminuria 16.47 13.05 5 10148 340 50594631
Synovitis 15.53 13.05 3 10150 123862 50471109
Hypertriglyceridaemia 15.42 13.05 11 10142 5480 50589491
Chronic kidney disease 15.15 13.05 28 10125 39743 50555228
Blood urea increased 15.04 13.05 21 10132 23564 50571407
Angioedema 14.95 13.05 27 10126 37649 50557322
Hyperlipidaemia 14.95 13.05 18 10135 17472 50577499
Infusion related reaction 14.47 13.05 8 10145 169549 50425422
Transient ischaemic attack 13.97 13.05 24 10129 32186 50562785
Myositis 13.86 13.05 12 10141 7908 50587063
Hypophagia 13.82 13.05 22 10131 27706 50567265
Blood creatine phosphokinase MB increased 13.82 13.05 6 10147 1136 50593835
Diabetes mellitus inadequate control 13.72 13.05 15 10138 13130 50581841
Granulocytopenia 13.60 13.05 10 10143 5221 50589750
Glaucoma 13.17 13.05 16 10137 15670 50579301
Joint swelling 13.16 13.05 18 10135 245268 50349703

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rhabdomyolysis 540.34 13.20 349 14268 60459 29499451
Acute kidney injury 112.77 13.20 336 14281 264931 29294979
Blood creatine phosphokinase increased 107.81 13.20 116 14501 40528 29519382
Myalgia 95.86 13.20 148 14469 73871 29486039
Blood triglycerides increased 95.06 13.20 66 14551 12768 29547142
Coronary artery disease 71.16 13.20 98 14519 44092 29515818
Myocardial infarction 58.71 13.20 152 14465 110144 29449766
Drug hypersensitivity 56.17 13.20 112 14505 68294 29491616
Polymyositis 52.45 13.20 21 14596 1307 29558603
Blood cholesterol increased 47.55 13.20 48 14569 15547 29544363
Off label use 45.63 13.20 49 14568 300751 29259159
Cardiac failure congestive 44.32 13.20 109 14508 76472 29483438
Drug interaction 40.06 13.20 198 14419 197187 29362723
Pancreatitis 36.44 13.20 63 14554 34451 29525459
Myopathy 29.54 13.20 31 14586 10502 29549408
International normalised ratio increased 28.71 13.20 66 14551 44306 29515604
Drug ineffective 27.64 13.20 90 14527 363080 29196830
Thunderclap headache 27.10 13.20 6 14611 43 29559867
Hyperglycaemia 25.58 13.20 54 14563 34233 29525677
Drug level below therapeutic 24.87 13.20 19 14598 4252 29555658
Chromaturia 24.61 13.20 31 14586 12771 29547139
Drug abuse 24.19 13.20 5 14612 79878 29480032
Haemodialysis 23.91 13.20 27 14590 9927 29549983
Chronic kidney disease 23.37 13.20 54 14563 36362 29523548
Granulocytopenia 23.10 13.20 21 14596 5973 29553937
Blood glucose increased 22.31 13.20 72 14545 58912 29500998
Death 20.68 13.20 93 14524 341991 29217919
Type 2 diabetes mellitus 20.17 13.20 29 14588 13552 29546358
Myositis 19.92 13.20 25 14592 10258 29549652
Product use in unapproved indication 19.91 13.20 9 14608 86866 29473044
Angioedema 19.04 13.20 46 14571 31869 29528041
Angina unstable 18.84 13.20 25 14592 10840 29549070
General physical health deterioration 18.83 13.20 14 14603 102843 29457067
Blood glucose decreased 18.26 13.20 26 14591 12043 29547867
Erosive duodenitis 18.05 13.20 10 14607 1297 29558613
Tricuspid valve incompetence 17.22 13.20 21 14596 8373 29551537
Reversible cerebral vasoconstriction syndrome 16.99 13.20 6 14611 263 29559647
Pyrexia 16.88 13.20 79 14538 287543 29272367
Treatment noncompliance 16.74 13.20 37 14580 24190 29535720
Lacrimation decreased 16.55 13.20 3 14614 6 29559904
Fanconi syndrome 16.18 13.20 10 14607 1588 29558322
Muscular weakness 16.07 13.20 67 14550 61985 29497925
Hypertriglyceridaemia 15.82 13.20 19 14598 7456 29552454
Pneumonia haemophilus 15.60 13.20 6 14611 335 29559575
Blood creatinine increased 15.54 13.20 83 14534 85019 29474891
Asthenia 15.28 13.20 168 14449 215082 29344828
Otitis externa 14.98 13.20 8 14609 965 29558945
Interstitial lung disease 14.84 13.20 5 14612 57713 29502197
Arteriosclerosis coronary artery 14.81 13.20 22 14595 10583 29549327
Hyperlipidaemia 14.63 13.20 24 14593 12566 29547344
Breast neoplasm 14.31 13.20 3 14614 16 29559894
Metabolic acidosis 14.26 13.20 46 14571 37616 29522294
Coronary artery stenosis 13.76 13.20 19 14598 8554 29551356
Renal tubular necrosis 13.64 13.20 25 14592 14290 29545620
Hyperlactacidaemia 13.62 13.20 11 14606 2667 29557243
Aortic valve sclerosis 13.51 13.20 7 14610 793 29559117
Chest pain 13.41 13.20 98 14519 111875 29448035
Paralysis 13.35 13.20 15 14602 5482 29554428

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rhabdomyolysis 707.11 12.63 410 20062 91316 64386944
Blood creatine phosphokinase increased 157.60 12.63 138 20334 58420 64419840
Blood triglycerides increased 157.36 12.63 89 20383 18777 64459483
Coronary artery disease 134.43 12.63 128 20344 60305 64417955
Acute kidney injury 125.71 12.63 369 20103 448871 64029389
Myocardial infarction 117.49 12.63 198 20274 165623 64312637
Myalgia 110.51 12.63 188 20284 158429 64319831
Drug hypersensitivity 88.13 12.63 217 20255 237598 64240662
Cardiac failure congestive 75.80 12.63 143 20329 130437 64347823
Drug interaction 66.89 12.63 259 20213 361824 64116436
Off label use 62.98 12.63 65 20407 632741 63845519
Pancreatitis 58.75 12.63 83 20389 59524 64418736
Myopathy 58.54 12.63 47 20425 17633 64460627
Drug ineffective 50.59 12.63 121 20351 840126 63638134
Polymyositis 46.97 12.63 21 20451 2689 64475571
Granulocytopenia 41.65 12.63 31 20441 10409 64467851
Hyperlipidaemia 37.12 12.63 41 20431 22935 64455325
Myositis 36.97 12.63 35 20437 16342 64461918
Hyperglycaemia 35.62 12.63 67 20405 60901 64417359
Chromaturia 34.22 12.63 39 20433 22572 64455688
Blood glucose increased 32.60 12.63 86 20386 97987 64380273
Acute interstitial pneumonitis 31.37 12.63 12 20460 1035 64477225
International normalised ratio increased 31.11 12.63 74 20398 79093 64399167
Chronic kidney disease 30.59 12.63 61 20411 57858 64420402
Blood cholesterol increased 30.47 12.63 56 20416 50010 64428250
Hypertriglyceridaemia 29.29 12.63 26 20446 11179 64467081
Angioedema 29.00 12.63 62 20410 61759 64416501
Drug intolerance 28.48 12.63 12 20460 187980 64290280
Muscular weakness 28.42 12.63 97 20375 127241 64351019
Blood creatinine increased 28.20 12.63 101 20371 135681 64342579
Treatment failure 26.56 12.63 3 20469 116813 64361447
Pyrexia 26.47 12.63 90 20382 558554 63919706
Drug abuse 26.41 12.63 5 20467 132369 64345891
Pancreatitis acute 26.16 12.63 48 20424 42807 64435453
Haemodialysis 25.07 12.63 29 20443 17048 64461212
Cerebrovascular accident 24.15 12.63 97 20375 137486 64340774
Blood glucose decreased 23.96 12.63 33 20439 23090 64455170
Angina unstable 23.95 12.63 27 20445 15440 64462820
General physical health deterioration 23.86 12.63 18 20454 204407 64273853
Renal failure 23.53 12.63 117 20355 181571 64296689
Type 2 diabetes mellitus 23.20 12.63 40 20432 33980 64444280
Hypoglycaemia 22.30 12.63 71 20401 89821 64388439
Acute myocardial infarction 21.02 12.63 59 20413 69659 64408601
Thunderclap headache 20.63 12.63 6 20466 220 64478040
Joint swelling 20.36 12.63 23 20449 215359 64262901
Erosive duodenitis 19.86 12.63 10 20462 1668 64476592
Infusion related reaction 19.81 12.63 14 20458 164453 64313807
Coronary artery stenosis 19.79 12.63 21 20451 11227 64467033
Treatment noncompliance 19.69 12.63 43 20429 43439 64434821
Cardiac disorder 19.62 12.63 50 20422 55766 64422494
Lip infection 18.99 12.63 5 20467 126 64478134
Chest pain 18.93 12.63 134 20338 235846 64242414
Arteriosclerosis coronary artery 18.93 12.63 24 20448 15505 64462755
High density lipoprotein decreased 18.67 12.63 13 20459 3933 64474327
Rheumatoid arthritis 18.49 12.63 15 20457 164279 64313981
C-reactive protein increased 18.07 12.63 4 20468 94905 64383355
Renal cyst 17.87 12.63 21 20451 12549 64465711
Blood urea increased 17.05 12.63 41 20431 44112 64434148
Bursitis 16.98 12.63 27 20445 21458 64456802
Intervertebral disc displacement 16.78 12.63 6 20466 428 64477832
Metabolic acidosis 16.65 12.63 55 20417 70903 64407357
Hypophagia 16.63 12.63 38 20434 39549 64438711
Fanconi syndrome 16.13 12.63 10 20462 2491 64475769
Tricuspid valve incompetence 15.75 12.63 23 20449 16980 64461280
Blood creatine phosphokinase MB increased 15.70 12.63 10 20462 2611 64475649
Product use issue 15.69 12.63 15 20457 151700 64326560
Hyperkalaemia 15.18 12.63 68 20404 101061 64377199
Condition aggravated 15.01 12.63 64 20408 372362 64105898
Myoglobinuria 14.97 12.63 7 20465 993 64477267
Coronary artery occlusion 14.66 12.63 20 20452 13871 64464389
Hypercholesterolaemia 14.54 12.63 21 20451 15352 64462908
Carotid artery stenosis 14.28 12.63 15 20457 7926 64470334
Ischaemic cardiomyopathy 14.27 12.63 14 20458 6824 64471436
Product complaint 13.82 12.63 18 20454 11936 64466324
Tendon rupture 13.70 12.63 17 20455 10750 64467510
Acute coronary syndrome 13.55 12.63 23 20449 19287 64458973
Product use in unapproved indication 13.51 12.63 22 20450 176596 64301664
Diabetes mellitus 13.41 12.63 49 20423 66425 64411835
Maternal exposure during pregnancy 13.16 12.63 7 20465 95877 64382383
Erectile dysfunction 13.05 12.63 18 20454 12609 64465651
Aspartate aminotransferase increased 12.67 12.63 73 20399 119715 64358545

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C10AB04 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, PLAIN
Fibrates
FDA CS M0199111 PPAR alpha
FDA MoA N0000175375 Peroxisome Proliferator-activated Receptor alpha Agonists
FDA EPC N0000175596 Peroxisome Proliferator Receptor alpha Agonist
CHEBI has role CHEBI:35679 antilipemic drugs
MeSH PA D000963 Antimetabolites
MeSH PA D065687 Cytochrome P-450 CYP2C8 Inhibitors
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D000960 Hypolipidemic Agents
MeSH PA D057847 Lipid Regulating Agents
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertriglyceridemia indication 302870006
Primary Prevention of Coronary Heart Disease indication
Hypoalphalipoproteinemia off-label use 190785000
Primary biliary cirrhosis contraindication 31712002 DOID:12236
Disorder of gallbladder contraindication 39621005 DOID:0060262
Acute nephropathy contraindication 58574008
Leukopenia contraindication 84828003 DOID:615
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409
Calculus in biliary tract contraindication 266474003
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Breastfeeding (mother) contraindication 413712001




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.13 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Peroxisome proliferator-activated receptor alpha Nuclear hormone receptor AGONIST EC50 4.23 IUPHAR CHEMBL
Transthyretin Secreted Kd 7 CHEMBL
Cytochrome P450 2C8 Enzyme Ki 5.74 WOMBAT-PK
Lipoprotein lipase Enzyme WOMBAT-PK
CDGSH iron-sulfur domain-containing protein 1 Unclassified Ki 5.14 CHEMBL
Cytochrome P450 2C9 Enzyme Ki 4.52 WOMBAT-PK
Fatty acid-binding protein, liver Unclassified Ki 5.73 CHEMBL

External reference:

IDSource
4018639 VUID
N0000146952 NUI
D00334 KEGG_DRUG
4018639 VANDF
C0017245 UMLSCUI
CHEBI:5296 CHEBI
4TX PDB_CHEM_ID
CHEMBL457 ChEMBL_ID
DB01241 DRUGBANK_ID
D015248 MESH_DESCRIPTOR_UI
3463 PUBCHEM_CID
3439 IUPHAR_LIGAND_ID
3899 INN_ID
Q8X02027X3 UNII
4719 RXNORM
4778 MMSL
523 MMSL
d00245 MMSL
002050 NDDF
35282000 SNOMEDCT_US
387189002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Lopid HUMAN PRESCRIPTION DRUG LABEL 1 0071-0737 TABLET, FILM COATED 600 mg ORAL NDA 18 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 0143-9130 TABLET, FILM COATED 600 mg ORAL ANDA 17 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 0143-9707 TABLET, FILM COATED 600 mg ORAL ANDA 18 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 0615-8354 TABLET, FILM COATED 600 mg ORAL ANDA 15 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 10544-569 TABLET, FILM COATED 600 mg ORAL ANDA 18 sections
Gemfibrozil Human Prescription Drug Label 1 16571-784 TABLET, FILM COATED 600 mg ORAL ANDA 15 sections
Gemfibrozil Human Prescription Drug Label 1 16714-101 TABLET 600 mg ORAL ANDA 18 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 21695-732 TABLET, FILM COATED 600 mg ORAL ANDA 17 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 24658-260 TABLET, FILM COATED 600 mg ORAL ANDA 17 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 31722-128 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 31722-225 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 33261-146 TABLET, FILM COATED 600 mg ORAL ANDA 17 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 42806-260 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 43063-745 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 43063-745 TABLET 600 mg ORAL ANDA 11 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 43063-921 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 43353-090 TABLET, FILM COATED 600 mg ORAL ANDA 18 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 43353-772 TABLET, FILM COATED 600 mg ORAL ANDA 21 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 43602-452 TABLET 600 mg ORAL ANDA 10 sections
Gemfibrozil Human Prescription Drug Label 1 50090-2450 TABLET, FILM COATED 600 mg ORAL ANDA 15 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 50090-2902 TABLET 600 mg ORAL ANDA 11 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 50090-5808 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 50268-350 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 51138-588 TABLET, FILM COATED 600 mg ORAL ANDA 18 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 51655-142 TABLET 600 mg ORAL ANDA 9 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 51655-143 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 53002-1068 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil Human Prescription Drug Label 1 53002-2068 TABLET, FILM COATED 600 mg ORAL ANDA 15 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 53217-251 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 53808-0251 TABLET, FILM COATED 600 mg ORAL ANDA 17 sections